Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taldefgrobep Alfa in Adults Living With Overweight and Obesity
NCT07281495Phase 2Active, not recruiting
- Sponsor
- Biohaven Ltd.
- Start
- Nov 2025
- Primary completion
- Sep 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of taldefgrobep alfa in obesity (4 arms), sponsored by Biohaven Ltd. Primary endpoint: Percent change in total body weight at 24 weeks. Started Nov 2025; status: active, not recruiting.
02
Drugs
taldefgrobep alfa
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07281495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07281495.